Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization
Executive Summary
A second Phase III multiple sclerosis trial testing the S1P1 modulator was positive, turning attention to whether or not Celgene will market the drug independently for the indication and how the drug might be positioned against an eventual generic Gilenya.